These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24279801)

  • 21. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
    Foley JE; Sreenan S
    Horm Metab Res; 2009 Dec; 41(12):905-9. PubMed ID: 19705345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
    Ahrén B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):487-98. PubMed ID: 19748066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
    Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
    Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vildagliptin in the treatment of type 2 diabetes mellitus.
    Stamataros G; Schneider SH
    Expert Opin Pharmacother; 2011 Aug; 12(12):1967-73. PubMed ID: 21679097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
    D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
    J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
    J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
    Fofonka A; Ribeiro JP; Casali KR; Schaan BD
    Trials; 2014 Nov; 15():424. PubMed ID: 25366037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation.
    Gueler I; Mueller S; Helmschrott M; Oeing CU; Erbel C; Frankenstein L; Gleißner C; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA; Doesch AO
    Drug Des Devel Ther; 2013; 7():297-303. PubMed ID: 23630415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
    Schweizer A; Foley JE; Kothny W; Ahrén B
    Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
    Bolli G; Dotta F; Colin L; Minic B; Goodman M
    Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.
    Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Wang Y; Dunning BE; Foley JE
    Diabetes Obes Metab; 2008 Nov; 10(11):1114-24. PubMed ID: 18355325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
    Kozlovski P; Fonseca M; Mohan V; Lukashevich V; Odawara M; Paldánius PM; Kothny W
    Diabetes Obes Metab; 2017 Mar; 19(3):429-435. PubMed ID: 27943546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
    Younis A; Eskenazi D; Goldkorn R; Leor J; Naftali-Shani N; Fisman EZ; Tenenbaum A; Goldenberg I; Klempfner R
    Cardiovasc Diabetol; 2017 May; 16(1):69. PubMed ID: 28532406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
    Fonseca V; Schweizer A; Albrecht D; Baron MA; Chang I; Dejager S
    Diabetologia; 2007 Jun; 50(6):1148-55. PubMed ID: 17387446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
    Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
    Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Jauffret S; Foley JE
    Diabetes Obes Metab; 2008 Aug; 10(8):675-82. PubMed ID: 18248490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.